Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10333911 | 1.00 | CA12 (0.41) | CA12CA9CA2SOAT1CYP1A2 | |
| SCHEMBL8383309 | 0.89 | SOAT1 (0.46) | CA12CA2SOAT1CYP1A2MEN1 | |
| SCHEMBL3747101 | 0.88 | SOAT1 (0.42) | CA12CA9CA2SOAT1CYP1A2 | |
| SCHEMBL899927 | 0.87 | TDP1 (0.37) | SOAT1CYP1A2MEN1FAAHTP53 | |
| SCHEMBL3288064 | 0.86 | KDM5A (0.46) | CA12CA9SOAT1CYP1A2MEN1 | |
| SCHEMBL808456 | 0.84 | TDP1 (0.36) | SOAT1CYP1A2MEN1FAAHTP53 | |
| SCHEMBL20998889 | 0.84 | TDP1 (0.36) | SOAT1CYP1A2MEN1FAAHTP53 | |
| Hydrochloric Acid SCHEMBL9711107 | 0.84 | ALOX15 (0.35) | SOAT1CYP1A2MEN1FAAHTP53 | |
| Ammonia Solution, Strong SCHEMBL10870270 | 0.84 | ALOX15 (0.35) | SOAT1CYP1A2MEN1FAAHTP53 | |
| Palmitic Acid SCHEMBL28958122 | 0.83 | GPR84 (0.59) | MEN1KMT2AALDH1A1TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3659580-B1 | CLEANSER COMPOSITION | KAO CORP (JP) | 2025-11-05 | — | — | EP | claimed |
| US-9328093-B2 | Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications | HYBRIGENICS SA (FR) | 2016-05-03 | — | — | US | claimed |
| US-20150072973-A1 | NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS | HYBRIGENICS SA (FR) | 2015-03-12 | — | — | US | claimed |
| EP-2523938-B1 | Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 | HYBRIGENICS SA (FR) | 2014-09-03 | — | — | EP | claimed |
| US-20130023521-A1 | NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS | HYBRIGENICS SA (FR) | 2013-01-24 | — | — | US | claimed |
| US-20110065703-A1 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM THERAPEUTICS LLC | 2011-03-17 | — | — | US | claimed |
| EP-2073799-A2 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM Discovery, Inc. (US) | 2009-07-01 | — | — | EP | claimed |
| WO-2008112715-A2 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM DISCOVERY INC. (US) | 2008-09-18 | — | — | WO | claimed |
| CN-1759095-A | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARM INC (US) | 2006-04-12 | — | — | CN | claimed |
| EP-1565428-A1 | SUBSTITUTED UREAS AND CARBAMATES | Elan Pharmaceuticals, Inc. (US) | 2005-08-24 | — | — | EP | claimed |
| WO-2004050609-A1 | SUBSTITUTED UREAS AND CARBAMATES | ELAN PHARMACEUTICAL, INC. (US) | 2004-06-17 | — | — | WO | claimed |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| US-9328093-B2 | Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications | HYBRIGENICS SA (FR) | 2016-05-03 | — | — | US | disclosed |
| US-20150072973-A1 | NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS | HYBRIGENICS SA (FR) | 2015-03-12 | — | — | US | disclosed |
| EP-2523938-B1 | Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 | HYBRIGENICS SA (FR) | 2014-09-03 | — | — | EP | disclosed |
| US-7351738-B2 | Substituted ureas and carbamates | ELAN PHARMACEUTICALS, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| EP-1754516-A2 | Hair cosmetic composition | KAO CORPORATION (JP) | 2007-02-21 | — | — | EP | disclosed |
| CN-1759095-A | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARM INC (US) | 2006-04-12 | — | — | CN | disclosed |
| EP-1565428-A1 | SUBSTITUTED UREAS AND CARBAMATES | Elan Pharmaceuticals, Inc. (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004050609-A1 | SUBSTITUTED UREAS AND CARBAMATES | ELAN PHARMACEUTICAL, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065703-A1 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | CACNA1G, CACNA1C, CACNA1B | CA12 2229/4885CA9 2116/4885CA2 138/4885 |
| US-20130023521-A1 | NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS | USP7, SENP7, PSMA7 | CA12 4166/4885CA9 3879/4885CA2 4296/4885 |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | ALDH1A2, PDE6D, PDE6C | CA12 1749/4885CA9 701/4885CA2 684/4885 |
| US-20150072973-A1 | NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS | USP7, SENP7, PSMA7 | CA12 4166/4885CA9 3879/4885CA2 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.